NCT02331303已完成不适用
A Drug Utilization Study of Xofigo Use in Sweden
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 37
- 主要终点
- Dosage of Xofigo (kBq/kg)
研究概览
简要总结
The objective of this study is to evaluate the extent of potential off-label use of Xofigo in Sweden.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients receiving Xofigo with data recorded at nuclear medicine centers in Sweden between 01 July 2014 and 30 June 2016 will be included in the study
排除标准
- •Patients receiving Xofigo in a clinical trial will not be included in this study
结局指标
主要结局
Dosage of Xofigo (kBq/kg)
时间窗: Up to 2 years
Proportion of being women of Xofigo use
时间窗: Up to 2 years
Proportion of bone metastasis but having a diagnosis of other cancer than mCRPV
时间窗: Up to 2 years
Proportion of participants of dose outside label recommendation
时间窗: Up to 2 years
Proportion of men with metastatic castration resistant prostate cancer (mCRPC) of Xofigo use
时间窗: Up to 2 years
Proportion of being children of Xofigo use
时间窗: Up to 2 years
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databases in DenmarkXGEVA Off-label UseNCT02066805Amgen142
已完成
不适用
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone MetastasesProstatic Neoplasms, Castration-ResistantNCT02803437Bayer334
已完成
不适用
Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the BoneCastration-resistant Prostate CancerNCT04232761Bayer194
已完成
2 期
BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant DiseaseBone MetastasesBreast CancerNCT01070485Bayer23
已完成
不适用
Safety and Efficacy Study of Oral XIGO Tablets to Treat The Common ColdCommon ColdNCT01092039Xigo Health LLC140